Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors in Zevra Therapeutics, Inc. (ZVRA) following significant stock price declines. The investigation focuses on whether Zevra's executive officers complied with federal securities laws after an $11.7 million inventory write-down and the resignation of its CFO led to investor losses. Shareholders who purchased Zevra securities and suffered losses are encouraged to contact Johnson Fistel for more information.
(ZVRA) and the Role of Price-Sensitive Allocations
The article provides a detailed analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting its near-term positive sentiment, mid-term weak bias, and long-term strength. It outlines various AI-generated institutional trading strategies including position trading, momentum breakout, and risk hedging, along with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels for different horizons.
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA) following significant stock price declines. The investigation focuses on Zevra’s executive officers and whether investor losses can be recovered under federal securities laws. Shareholders who suffered losses are encouraged to contact Johnson Fistel for more information.
Zevra Therapeutics opens Nasdaq with bell ceremony
Zevra Therapeutics participated in the Nasdaq opening bell ceremony, marking a significant achievement for the company. This event highlights Zevra Therapeutics' commitment to operational progress and market presence. Nasdaq opening bell ceremonies typically recognize organizations with notable accomplishments or milestones within the financial community.
Responsive Playbooks and the ZVRA Inflection
This article analyzes Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting a weak near-term sentiment but strong long-term potential, characterized by a mid-channel oscillation pattern. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, showing varying support and resistance levels across different time horizons. The report suggests potential choppiness due to divergent sentiments and offers institutional-grade analysis for subscribers.
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
Zevra Therapeutics unveiled encouraging new real-world data at the 22nd Annual WORLDSymposium™ regarding its drug MIPLYFFA® (arimoclomol) for Niemann-Pick Disease Type C (NPC). The data, spanning up to four years, indicate that MIPLYFFA is well-tolerated and effectively stabilizes disease progression in both pediatric and adult NPC patients. Notably, a post-hoc analysis of the NPC002 trial showed a statistically significant slowing of disease progression when MIPLYFFA was combined with miglustat, with benefits observed as early as three months into treatment.
Timothy Sangiovanni Sells 3,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock
Timothy Sangiovanni, SVP of Zevra Therapeutics (NASDAQ:ZVRA), sold 3,000 shares of company stock on February 3rd at an average price of $9.18, totaling $27,540. This transaction reduced his stake by 9.21% to 29,590 shares. ZVRA shares were trading down 2.4% at $8.94 with an average analyst target price of $22.80, indicating a "Moderate Buy" consensus.
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) announced it will ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, the company's President and CEO, will deliver remarks before the bell ceremony, which signifies the start of the trading session. The event can be viewed live online and on the Nasdaq MarketSite Tower in New York.
Zevra Therapeutics Presents Positive Data on MIPLYFFA® for Niemann-Pick Disease Type C at WORLDSymposium™ 2026
Zevra Therapeutics announced positive new data for its therapy MIPLYFFA® (arimoclomol) for Niemann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™. The studies demonstrated MIPLYFFA's effectiveness in stabilizing disease progression across a broad range of NPC patients, including adults, over four years in real-world settings and showed statistically significant health improvements as early as three months in a pivotal trial. Zevra is committed to advancing rare disease therapies and has submitted a Marketing Authorization Application for arimoclomol to the European Medicines Agency.
4 years of real-world data track MIPLYFFA in rare Niemann-Pick disease
Zevra Therapeutics presented positive four-year real-world data and post hoc analysis results for MIPLYFFA in Niemann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium. The data indicates that MIPLYFFA was well-tolerated and stabilized disease progression in both pediatric and adult NPC patients, with statistically significant slowing of progression observed as early as three months into treatment in a post hoc analysis of the NPC002 trial. These findings strengthen the understanding of MIPLYFFA's impact and provide robust evidence for its long-term safety and effectiveness.
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
Zevra Therapeutics presented positive new real-world data on MIPLYFFA® (arimoclomol) for Niemann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™. The data from real-world studies and clinical trials showed that MIPLYFFA was well-tolerated and stabilized disease progression in both pediatric and adult NPC patients, with sustained benefits over long-term use. This reinforces the therapy's effectiveness and safety profile across a broad spectrum of patients.
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
Zevra Therapeutics announced new positive real-world data on its drug MIPLYFFA (arimoclomol) for Niemann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™. The data from various studies and an Early Access Program demonstrated the long-term safety and effectiveness of MIPLYFFA in stabilizing disease progression in both pediatric and adult NPC patients, including those treated with a combination of MIPLYFFA and miglustat. This evidence reinforces the drug's sustained clinical benefit and favorable safety profile, particularly for the adult NPC population.
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock
Joshua Schafer, Chief Commercial Officer of Zevra Therapeutics, sold 3,375 shares of ZVRA stock for approximately $29,800 on January 30th, 2026. This transaction occurred after he acquired 11,333 and 35,334 shares through option exercises on January 30th and 31st, respectively, and was also granted Restricted Stock Units and Stock Options on January 29th. The article also notes Zevra's recent Q3 2025 earnings which exceeded EPS expectations and a maintained Buy rating from H.C. Wainwright.
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock
Joshua Schafer, Chief Commercial Officer of Zevra Therapeutics, sold 3,375 shares of ZVRA stock for approximately $29,800 after exercising options to acquire a larger number of shares and receiving Restricted Stock Units and Stock Options. This transaction follows Zevra's Q3 2025 earnings report where EPS surpassed expectations but revenue slightly missed, and an exclusive distribution agreement with Uniphar for its Miplyffa program. H.C. Wainwright has maintained a Buy rating with a $26.00 price target for Zevra.
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $40,026.39 in Stock
Zevra Therapeutics (NASDAQ:ZVRA) insider Adrian Quartel sold 4,533 shares of the company's stock for $40,026.39 on January 30th, reducing his stake by 31.8%. The stock is currently trading around $9.36, with a market cap of $526.97 million and a PE ratio of 19.91. Analysts currently have a "Moderate Buy" rating for ZVRA, with an average price target of $22.80.
Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock
Zevra Therapeutics CEO Neil Mcfarlane sold 91,000 shares of the company's stock on February 2nd, 2026, for a total of $853,580, reducing his stake by nearly 20%. Following the sale, he now owns 364,350 shares of ZVRA, valued at approximately $3.42 million. The stock traded up 4.0% to $9.36 on the day of the transaction.
Zevra Therapeutics CEO McFarlane sells $853k in shares
Zevra Therapeutics CEO Neil F. McFarlane sold 91,000 shares of common stock for approximately $853,425 on February 2, 2026. This transaction followed his exercise of options to acquire 233,334 shares and the grant of restricted stock units and stock options in late January. The news comes after the company reported mixed Q3 2025 financial results, exceeding EPS expectations but slightly missing revenue forecasts, while H.C. Wainwright reiterated a Buy rating with a $26.00 price target.
Why this rare-disease drug maker is ringing Nasdaq's opening bell
Zevra Therapeutics will ring the Nasdaq opening bell on Monday, February 9, 2026, with CEO Neil F. McFarlane delivering opening remarks. This event is primarily to increase corporate visibility rather than to announce fundamental changes, highlighting the company's recent operational improvements including significant Q3 2025 revenue growth and reduced losses, alongside commercialization efforts for its lead rare disease product, MIPLYFFA®. Investors are encouraged to focus on future earnings, commercial execution, and clinical updates for more material drivers.
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) announced it will ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, the company's President and CEO, will deliver remarks before the 9:30 a.m. ET bell ringing. The event signifies Zevra's presence as a commercial-stage company focused on rare disease therapies.
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
Zevra Therapeutics, a commercial-stage company focused on rare diseases, announced it will ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, Zevra's President and CEO, will deliver opening remarks before the bell ringing at 9:30 a.m. ET. The ceremony can be viewed live online or at the Nasdaq MarketSite Tower.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Moderate Buy" from Analysts
Zevra Therapeutics (NASDAQ:ZVRA) has received a consensus rating of "Moderate Buy" from eight analysts, with an average one-year price target of $22.80. The company's stock is currently trading around $9, with a market cap of $507 million, and recently beat quarterly EPS estimates. Zevra is advancing its lead candidate KP1077 (for idiopathic hypersomnia) through Phase 2 trials and has other early-stage programs for narcolepsy and vascular Ehlers-Danlos syndrome.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Down 32.5% in January
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) saw a significant decrease in short interest in January, with shares short sold falling by 32.5% to 3,991,736. The company's stock opened at $9.00, has a market cap of approximately $506.7 million, and a P/E ratio of 19.15. Analysts currently rate ZVRA as a "Moderate Buy" with an average target price of $22.80, pointing to its clinical-stage pipeline which includes treatments for idiopathic hypersomnia, narcolepsy, and vascular Ehlers-Danlos syndrome.
Understanding the Setup: (ZVRA) and Scalable Risk
This article analyzes Zevra Therapeutics Inc. (ZVRA) using AI models, identifying a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional short setup with a 56.0:1 risk-reward ratio and outlines specific institutional trading strategies for long, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report provides entry and exit zones, targets, and stop losses for various risk profiles.
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
Zevra Therapeutics announced that four abstracts detailing data and clinical experience with MIPLYFFA® (arimoclomol) will be presented at the 22nd Annual WORLDSymposium™. This includes an oral presentation by Dr. Caroline Hastings on four-year real-world safety and efficacy data for MIPLYFFA in Niemann-Pick Disease Type C (NPC) patients. The company will also host a satellite symposium focusing on diagnostic and therapeutic challenges in NPC.
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
Zevra Therapeutics will present multiple analyses on MIPLYFFA® (arimoclomol) at the 22nd Annual WORLDSymposium™, including an oral presentation on four-year real-world safety and efficacy data. Four abstracts related to MIPLYFFA in Niemann-Pick disease type C (NPC) have been accepted, with additional poster presentations covering U.S. Early Access Program outcomes, subgroup analyses, and efficacy results from a randomized trial. The company will also host a satellite symposium focusing on diagnostic and therapeutic advancements in NPC.
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
Zevra Therapeutics announced that four abstracts detailing clinical data and real-world experience with MIPLYFFA (arimoclomol) have been accepted for presentation at the 22nd Annual WORLDSymposium™. Dr. Caroline Hastings will deliver an oral presentation on four-year real-world safety and efficacy data for MIPLYFFA in Niemann-Pick Disease Type C (NPC) patients. Additionally, Zevra will host a satellite symposium focusing on diagnostic and therapeutic challenges in NPC.
Delaware Chancery Court Ruling Finds a Security Interest is a “Transfer” – Commave v. Zevra
The Delaware Court of Chancery recently ruled in Commave v. Zevra that granting a lien on a license agreement as collateral for a loan constituted an "assignment" and "transfer" of payments. This decision is significant because security interests are not typically considered transfers until default and foreclosure. The court's focus on the license agreement's broad definition of "Payment Assignment" and specific carve-outs for prior security interests led to this finding, advising parties to explicitly define security interests in transfer clauses to avoid future complications.
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
Zevra Therapeutics will present multiple analyses on its drug MIPLYFFA at the 22nd Annual WORLDSymposium. The presentations will include clinical data and real-world experience, featuring a podium presentation on four-year real-world safety and efficacy data in patients with Niemann-Pick Disease Type C (NPC). The company will also host a satellite symposium focusing on diagnostic and therapeutic challenges in NPC.
The Technical Signals Behind (ZVRA) That Institutions Follow
This article provides a technical analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA) based on AI-generated signals. It highlights a near-term strong sentiment, mid-channel oscillation, and specific risk-reward setups, along with three distinct institutional trading strategies for different risk profiles. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for ZVRA.
J.P. Morgan: Zevra Sees EU As Land Of Opportunity For Miplyffa
J.P. Morgan suggests that Zevra Therapeutics views Europe as a promising market for its product, Miplyffa. The article highlights Zevra's active pursuit of opportunities within the EU. It also mentions that Scrip provides weekly updates on top pharma business news, including rare diseases and deals.
J.P. Morgan: Zevra Sees EU As Land Of Opportunity For Miplyffa
According to J.P. Morgan, Zevra Therapeutics is actively exploring opportunities in Europe for its product Miplyffa. The article highlights Zevra's strategic focus on the European market, as observed by J.P. Morgan. This indicates a potential expansion of Zevra's presence and market reach within the EU.
Is Zevra Therapeutics (ZVRA) Using J.P. Morgan Spotlight To Reframe Its Rare-Disease Investment Story?
Zevra Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference, using the platform to highlight its rare disease focus and pipeline. This appearance aims to reframe its investment narrative, especially concerning its lead candidate MIPLYFFA and its European reimbursement ambitions, despite past setbacks with OLPRUVA. The company projects significant revenue and earnings growth by 2028, with fair value estimates suggesting a substantial upside for investors.
Is Zevra Therapeutics (ZVRA) Using J.P. Morgan Spotlight To Reframe Its Rare-Disease Investment Story?
Zevra Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference, using the platform to highlight its rare disease focus and pipeline. The article discusses how this high-profile appearance could influence Zevra's investment narrative, particularly regarding its lead asset, MIPLYFFA, and European reimbursement ambitions, while also noting past impairments related to OLPRUVA. Despite varied fair value estimates from the community, the company's financial narrative forecasts significant revenue and earnings by 2028, suggesting a substantial upside to its current price according to Simply Wall St's analysis.
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) reported a Q4 loss of $0.18 per share, which is narrower than the Zacks Consensus Estimate of a $0.20 loss. The company's quarterly revenues reached $8.6 million, surpassing the consensus estimate by 50.88% and showing significant growth compared to the prior-year quarter. This positive revenue performance highlights Zevra's strong commercial execution and market reception for its products.
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
Zevra Therapeutics, Inc. announced that its executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. PT. Management will also be available for one-on-one meetings with registered attendees. Zevra is a commercial-stage company focused on providing therapies for rare diseases, with a lead product for Niemann-Pick disease type C and a pipeline of other rare disease programs.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received an average "Moderate Buy" rating from analysts, with a mean one-year price target of $22.80. The company's CEO recently reduced his stake, while institutional ownership stands at approximately 35.03% following significant purchases. Zevra surpassed quarterly EPS estimates but slightly missed revenue projections, currently trading around $8.34 with a market capitalization of nearly $470 million.
Zevra Therapeutics to Present at J.P. Morgan 44th Annual Healthcare Conference on January 15, 2026
Zevra Therapeutics announced its participation in the J.P. Morgan 44th Annual Healthcare Conference, where its executive leadership will present on January 15, 2026, at 9:45 a.m. PT. The company, which specializes in rare disease therapies, will discuss its lead product for Niemann-Pick disease type C, geographic expansion plans, and its pipeline of rare disease programs. Investors can access a live webcast of the presentation on Zevra's investor relations website.
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
Zevra Therapeutics, a commercial-stage company focusing on therapies for rare diseases, announced that its executive leadership will present at the J.P. Morgan 44th Annual Healthcare Conference on January 15, 2026. Management will also be available for one-on-one meetings with registered attendees. A webcast of the presentation will be available on the company's investor relations website.
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
Zevra Therapeutics announced that its executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference on January 15, 2026, at 9:45 a.m. PT. Management will also be available for one-on-one meetings with registered attendees. A live webcast of the presentation will be available on the company's Investor Relations website.
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
Zevra Therapeutics announced that its executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference on January 15, 2026, at 9:45 a.m. PT. Management will also be available for one-on-one meetings, and a live webcast of the presentation will be accessible on the company's investor relations website. Zevra Therapeutics is a commercial-stage company focused on providing therapies for rare diseases.
Precision Trading with Zevra Therapeutics Inc. (ZVRA) Risk Zones
This article provides a precision trading analysis for Zevra Therapeutics Inc. (ZVRA), highlighting weak near-term sentiment but an exceptional 86.0:1 risk-reward setup targeting a 21.3% gain. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to manage risk and optimize returns. The report emphasizes the use of AI-generated signals for real-time entry and exit points.
Is Zevra Therapeutics (ZVRA) Using Expanded Access To Quietly Recast Its Rare-Disease Growth Story?
Zevra Therapeutics has entered into an exclusive expanded access distribution agreement with Uniphar for MIPLYFFA (arimoclomol), aimed at broadening treatment availability for Niemann-Pick Disease Type C patients outside Europe. This move could reshape Zevra's rare-disease growth narrative, especially as it seeks European regulatory approval and reimbursement, despite past setbacks with OLPRUVA. The company forecasts substantial revenue and earnings growth by 2028, with a projected fair value of $23.22, though analyst estimates vary widely.
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Zevra Therapeutics (ZVRA)
Two healthcare companies, Ultragenyx Pharmaceutical (RARE) and Zevra Therapeutics (ZVRA), have received bullish sentiments from analysts. J.P. Morgan maintained a Buy rating on Ultragenyx with a $120.00 price target, while Canaccord Genuity reiterated a Buy rating on Zevra Therapeutics with a $24.00 price target. Both companies are seen as strong buys with significant upside potential according to the analyst consensus.
Zevra Therapeutics stock maintains Buy rating at H.C. Wainwright on expanded access deal
H.C. Wainwright has reiterated a Buy rating and a $26.00 price target for Zevra Therapeutics (NASDAQ:ZVRA) following an expanded access distribution agreement for Miplyffa (arimoclomol). This agreement, which adds new territories for Niemann-Pick Disease Type C patients, is not yet factored into the stock's current valuation, suggesting significant upside. The company recently reported Q3 2025 EPS of -$0.01, beating analyst forecasts, despite a slight revenue shortfall.
New deal expands access to a vital Niemann-Pick C treatment beyond Europe
Zevra Therapeutics has partnered with Uniphar to expand patient access to MIPLYFFA (arimoclomol) for Niemann-Pick Disease Type C (NPC) in territories outside Europe. The agreement focuses on reimbursed named-patient supply, leveraging Uniphar's global distribution while Zevra continues U.S. commercialization and pursues EU approval. MIPLYFFA is FDA-approved in the U.S. and has shown significant clinical benefits, including halting disease progression and a durable effect for over five years.
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)
Zevra Therapeutics has signed an exclusive expanded access distribution agreement with Uniphar to broaden access to MIPLYFFA® (arimoclomol) for Niemann-Pick Disease Type C (NPC) patients in select territories outside of Europe. MIPLYFFA is an FDA-approved therapy shown to halt NPC progression, and its Marketing Authorisation Application is currently under review by the European Medicines Agency. This partnership aims to address unmet needs in the rare disease community by leveraging Uniphar's global distribution expertise.
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics announced the grant of inducement options for 53,000 shares of common stock to three new employees. These grants, made under Nasdaq Rule 5635(c)(4), are intended to incentivize individuals joining the company and vest over four years. Zevra is a commercial-stage company focused on developing therapies for rare diseases.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Brokerages
Zevra Therapeutics (NASDAQ:ZVRA) has received a "Moderate Buy" consensus from eight analysts, with an average 12-month price target of $22.80. This comes despite some recent downgrades and price target reductions from individual brokerages. The article also notes insider selling by CEO Neil F. Mcfarlane, juxtaposed with significant institutional buying from firms like Cantor Fitzgerald and NewEdge Advisors.
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics announced the grant of inducement options to purchase 53,000 shares of its common stock to three new employees. These grants were made under the company's 2023 Employment Inducement Award Plan, in accordance with Nasdaq Rule 5635(c)(4), and vest over four years. This action is part of Zevra's strategy to attract and retain talent in its focus on rare disease therapies.
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics has granted stock options for 53,000 shares to three new employees under its 2023 Employment Inducement Award Plan. These awards vest over four years and were made as a material inducement for their employment, following Nasdaq Rule 5635(c)(4). The plan is specifically designed to grant equity awards to new hires to encourage their entry into employment with Zevra.
